Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Period	Debt/Equity
2020-12-31	0.05
2021-12-31	0.17
2022-12-31	0.51
2023-12-31	0.26
2024-12-31	0.08

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$320.22	+0.00%	0.33M
3
4
5

Praxis Precision Medicines Inc. (PRAX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Praxis Precision Medicines Inc. Data in Excel

More PRAX Financial Data